Month: November 2016
Efforts to develop antibodies that can ferry drugs into cancer cells and minimize damage to healthy tissue are gathering steam. The next generation of these ‘weaponized antibody’ therapies, called antibody–drug conjugates (ADCs), is working its way through clinical trials.
NgAgo gene-editing, claiming to be a better alternative to CRISPR gene editing, falls into a controversy in peer-reviewed papers
Six months ago, Chinese researchers reported that an enzyme called NgAgo could be used to edit mammalian genes – and that it might be more accurate and more versatile than the popular CRISPR-Cas9 gene-editing technique. But almost immediately, other scientists complained on internet forums that they could not replicate the experiment.
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology, closely associated with interstitial lung disease that shows similar symptoms but with different mode of action. The disease is known so because it primarily involves the interstitium, where scars develop and progress
The latest news in the ever evolving universe of CRISPR gene technology is that the editing tool has been used for the first time in humans to cure aggresive lung cancer by a team of Chinese researchers. Read about it :